Summary

Overview
Global At-Home Drug of Abuse (DOA) Testing market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Drug abuse testing is a procedure that tests for illicit or improperly utilized prescription medication in a person's system. Drug tests may take a variety of forms, each with unique benefits and drawbacks.
Drugs of Abuse (DOA) tests are used to screen for the presence of abused drugs in a specimen obtained from a subject in a clinic, home, workplace, sports, or insurance setting. Tests in blood, urine, sweat, saliva, hair or other specimen matrices are possible.
Market Dynamics: Drivers & Restraints
The increasing overdose of drugs and diagnosis of these drugs
The leading cause of drug overdose deaths is opioids, particularly synthetic opioids (other than methadone). A public health crisis is triggered by an unexpected rise in drug overdose deaths. Even with prescription medications, people are becoming more conscious of the risks associated with substance abuse and the possibility of addiction.
Due to increased knowledge, there is a larger need for instruments to track drug usage, both for oneself and possibly for loved ones who are addicted. For instance, according to the report by the National Institute of Drug Abuse in 2022, nearly 108,000 persons in the U.S. died from drug-involved overdose in 2022, including from illicit or prescription drugs.
These tests, however, may be used to monitor treatment and recovery. Hence, the increasing number of drug overdose cases and their diagnosis is expected to drive the market.
Limitations of these testing devices
A drug test result for a urine specimen that contains an unidentified adulterant or an interfering substance, has abnormal physical characteristics, or contains an endogenous substance at an abnormal concentration, preventing at-home drug tests from completing or obtaining a valid drug test result. This test's at-home component is fairly sensitive to the presence of drugs in the urine.
For more details on this report ? Request for Sample
Segment Analysis
The global at-home drug of abuse testing market is segmented based on product type, sample and region.
Rapid DOA Test Kits segment is expected to dominate the market growth
Rapid Screen tests use one-of-a-kind monoclonal antibodies to detect specific drugs of abuse (DOA) and their metabolites in urine samples with high sensitivity and specificity. DOA rapid tests are qualitative, lateral flow devices based on the drug-competitive inhibition immunoassay.
The cut-off concentration for specific drug of abuse and its metabolites has been developed for all of our DOA screening test devices at the concentration standards set by NIDA (the National Institute on Drug Abuse of the United States) for the qualitative detection of corresponding drugs in human urine specimens.
For example, Atlas medical a UK based company’s, Atlas Medical Drug of Abuse (DOA) Rapid Tests can detect a wide variety of drugs in urine and saliva samples. The tests are based on lateral flow immunoassay rapid tests and are available in strip, cassette, multi-dip, multi-cassette, and multi-drug cup formats for professional, forensic, and work-screening applications. Atlas Medical can provide custom drug combinations to customers in addition to the standard selection of multi-drug tests. Their DOA breath analyzers are simple to use and provide clear, accurate, and consistent results.
Geographical Analysis
North America is expected to hold a significant position in the at-home drug of abuse testing market share
North America region accounted for the largest market share in the global at-home drug of abuse testing market. The accessibility and consumption of illegal drugs is a serious problem in North America. This increases the need for easy-to-use drug monitoring tools, whether for private or court-ordered purposes.
For instance, according to a report in 2022 by the Addiction Center, it stated that addiction is a serious problem that affects millions of people and more than 70% of people who tried an illegal drug before the age of 13 have an addiction to alcohol or drugs. Almost 21 million Americans have at least one addiction, yet only 10% of them receive treatment. About 25% of people who use illicit drugs develop an addiction.
Additionally, according to the results released by the US Department of Health and Human Services in 2023, it reported that among people aged 12 or older in 2021, 61.2 million people (or 21.9 percent of the population) used illicit drugs in 2022. The most commonly used illicit drug was marijuana, which 52.5 million people used. Thus, the above factors are expected to hold the region in the dominant position during the forecast period.
COVID-19 Impact Analysis
Due to the strict lockdown measures and social distancing implemented to combat the spread of the coronavirus, an increase in alcohol and drug abuse has resulted, which has led to isolated overdosing and posing a significant challenge for drug addicts. Hence, with the lockdown restrictions, people preferred at-home drug abuse testing.
Market Segmentation
By Product Type
- Rapid DOA Test Kits
- Test cups
- Test dip cards
- Test strips
- Other
- Breath Analyzers
- Other
By Sample
- Urine
- Saliva
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include UCP Biosciences Inc., Atlas Medical, Assure Tech (Hangzhou) Co. Ltd., Biopanda Reagents, Home Health (U.K.) Ltd., Phamatech, Inc., Psychemedics Corporation, Cliawaived, Inc., Co-Innovation Biotech Co., Ltd. and MyDiagnostics among others.
Why Purchase the Report?
- To visualize the global at-home drug of abuse testing market segmentation based on product type, sample and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of at-home drug of abuse testing market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global at-home drug of abuse testing market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Sample
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing launches of advanced minimally invasive surgery devices
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High costs of minimally invasive surgery devices
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Rapid DOA Test Kits *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Test cups
7.2.4. Test dip cards
7.2.5. Test strips
7.2.6. Other
8. Breath Analyzers
9. Other
10. By Sample
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample
10.1.2. Market Attractiveness Index, By Sample
10.2. Urine *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Saliva
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.3.1. U.S.
11.2.3.2. Canada
11.2.3.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.4.1. Germany
11.3.4.2. UK
11.3.4.3. France
11.3.4.4. Italy
11.3.4.5. Spain
11.3.4.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.4.1. Brazil
11.4.4.2. Argentina
11.4.4.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.4.1. China
11.5.4.2. India
11.5.4.3. Japan
11.5.4.4. South Korea
11.5.4.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. UCP Biosciences Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Atlas Medical
13.3. Assure Tech (Hangzhou) Co. Ltd.
13.4. Biopanda Reagents
13.5. Home Health (U.K.) Ltd.
13.6. Phamatech, Inc.
13.7. Psychemedics Corporation
13.8. Cliawaived, Inc.
13.9. Co-Innovation Biotech Co.,Ltd.
13.10. MyDiagnostics
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us